|
Hi ,
I am giving a special shout-out to my friends in the North Carolina synthetic biology community for some recent standout success! Raleigh-based Jellatech recently landed $3.5M in seed funding to enable the scale-up of their cutting-edge protein manufacturing platform. Additionally, the plant-based dog food company Wild Earth, out of Durham, NC, just partnered with Petco to launch its fully vegan line of dog food and treats. So, a big congratulations to the North Carolina crew!
-
Have you tried My®Bacon yet? If you haven't, what are you waiting for!? Ecovative and My®ForestFoods are on a mission to bring biology to scale, which means bringing their delicious plant-based bacon to a thousand stores in the coming year. Their farm-grown mycelium gives MyBacon a remarkable taste and texture. Check out this short video for more information.
|
 |
|
(Photo: Business Wire)
-
Pioneering Gene Therapy Results Promising for Rare Liver Disease. In a monumental clinical trial, Généthon's gene therapy emerges as a game-changer, turning the tide against Crigler-Najjar syndrome.
-
Green is the New Gold: Cascade Biocatalysts Secures $2.6M to Scale Enzyme Technology. Cascade’s breakthrough "Body Armor for Enzymes™" technology gains momentum from pre-seed funding.
-
Retinol Revolution: Conagen's Sustainable Spin on Skincare. Through precision fermentation, Conagen pioneers a sustainable retinol blend, revolutionizing beauty and personal care formulations
-
Inside the Belly's Bazaar: Probiotics that Light Up Inflammation. Rice University's bioengineers are turning the spotlight on gut health with their glow-on-demand probiotics, designed to detect inflammation.
-
Aviation and Maritime Biofuels Get Sustainability Boost from Novel Enzyme. Brazilian researchers unveil OleTPRN, a groundbreaking enzyme poised to redefine the biofuel landscape for global aviation.
-
Nanovesicles: The Tiny Sacks Engineered to Target Cancer Cells. Gone might be the days of toxic chemotherapies, as Binghamton University pioneers a safer, targeted method using nanovesicles.
-
A DNA-Based Anticoagulant is Set to Disrupt the Norm. Bridging biochemistry and thrombosis biology, researchers are crafting a revolutionary anticoagulant poised to change the future of blood clot treatments.
-
Unlocking Nature's Secrets: The Promise of Synthetic Catalysts in Biomass Conversion. Inspired by nature's enzymes, Iowa State scientists’ groundbreaking research into synthetic catalysts offers a sustainable path to biomass conversion.
|
|
|
|
|
|
|
|
|
|
|
|
|
Other news: |
|
-
iGEM Hosts the World Expo of Synthetic Biology in Paris: Experience the largest gathering of synthetic biology from Nov 2 to Nov 5, 2023. Join over 5000 researchers, industry reps, startup founders, investors, journalists, experts in governance and policy, and the general public to chart the future of synthetic biology.
-
Genesis Therapeutics Closes Oversubscribed $200 Million Series B. The funds will be used to advance Genesis’ existing wholly-owned pipeline of AI-enabled programs into clinical development. (Press release)
-
Aether Raises $49M in Series A Funding. Aether, a Menlo Park, CA-based nanoscale machinery company that can assemble new classes of molecules to create enhanced products, raised $49M in Series A funding. (FinSMEs)
-
Scottish startup ENOUGH raises €40m for its alternative meat. Founded in 2015, ENOUGH has now raised more than €95m, making it Europe’s best-funded mycoprotein startup (Sifted)
-
Innovate Illinois, led by Governor JB Pritzker, has supported two groundbreaking projects in a collaborative effort to secure federal funding made available by the Bipartisan Infrastructure Bill, the CHIPS and Science Act, and the Inflation Reduction Act.
-
Global Life Sciences/Healthcare Startup Class Briefing. Learn about UCSF's renowned global entrepreneurship course that starts on October 4th.
Regards,
John
---
John Cumbers
CEO, SynBioBeta
|
|
Who's hiring? |
|
|
|
|
|
|
|
|
